Minerva Neurosciences (NERV) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 50.0% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($169.7 million vs $153.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | VRXA |
|---|---|---|
| Share price | $3.22 | $1.20 |
| Market cap | $153.75M | $169.69M |
| 1-day change | -1.53% | 0.00% |
| YTD return | -18.66% | -88.75% |
| 1-year return | +50.00% | -88.53% |
| 5-year return | -69.72% | — |
| EPS (TTM) | $-36.12 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $27.36 |
| 52-week low | $2.24 | $1.04 |
| Distance from 52-week high | -74.16% | -95.61% |
| Analyst consensus | none | — |
| Avg. price target upside | +220.81% | — |
| Average volume | 184.44K | 274.75K |
| Shares outstanding | 47.75M | 141.41M |
| Employees | 7 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed VRXA by 138.5 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
NERV vs VRXA FAQ
Which is bigger, Minerva Neurosciences or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $169.69M compared with $153.75M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or VRXA?
NERV returned +50.00% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.